Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On September 20, 2021, Annexon (Nasdaq: ANNX) announced its upcoming virtual C1q Series event scheduled for September 27, 2021, at 10:00 a.m. ET. This event will focus on the company's neurodegeneration franchise and will include presentations from the executive team and key opinion leaders. A live webcast will be accessible through the Investors section of annexonbio.com. Annexon specializes in developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders, leveraging its technology to target diseases caused by C1q activation.
Details
News Market Reaction – ANNX
The recorded move for ANNX in the trading session of this news was -4.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain and eye, today announced that the company will host its second virtual C1q Series event on Monday, September 27, 2021, at 10:00 a.m. ET, to discuss its neurodegeneration franchise. Annexon’s R&D event will include presentations from the executive team as well as prominent key opinion leaders.
A live webcast and slide presentation will be available in the “Events and Presentations” page of the “Investors” section of annexonbio.com. To register for this event, please access the online registration link here.
About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.
Contacts:
Investors:
Jennifer Lew
Chief Financial Officer, Annexon Biosciences
jlew@annexonbio.com
Media:
Miriam Mason
Annexon Biosciences
mmason@annexonbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.